With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna.  | Late Thursday, PTC revealed that ...

In a statement, PTC's chief executive, Matthew Klein, said the company had decided to pull the filing for Translarna (ataluren) as a treatment for nonsense mutation DMD after the FDA said it was ...

Anavex Life Sciences faces regulatory setbacks after the EMA adopted a negative opinion of blarcamesine in Alzheimer's. Find ...

T o make good decisions on any question the public needs to be well-informed, something not so easily accomplished in America’s schools. That is a key point made by Michael Kent, a recently retired ...

With regard to Anavex 3-71, we will be advancing Anavex 3-71 towards pivotal clinical studies for the treatment of schizophrenia-related disorders. And now I would like to direct the call to Sandra ...

At the Contemporary Forum, Late-breaking Science and the Rapid Fire Competition, Shrijay Vijayan, Ph.D., MBA, Polaryx Therapeutics’ Chief Scientific and Business Development Officer, presented ...

Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2026 Earnings Call Transcript February 9, 2026 Anavex Life Sciences Corp. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.1.

The report identifies substantial opportunities in developing EZH2-targeted therapies for cancer treatment, highlighting current clinical trials and the potential for innovation in precision medicine.

After decades of fixating on mutations in nuclear DNA as the prime suspects in cancer development, researchers are increasingly peering into the cell’s powerhouse for clues. Mutations in mitochondrial ...

ATRX, a gene involved in organising and maintaining DNA structure within cells, is commonly altered in neuroblastoma. While the presence of ATRX mutations has long been associated with certain disease ...